Cargando…

Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?

Epidemiological aspects of Parkinson's disease (PD), co-occurring diseases and medical healthcare utilization of PD patients are still largely elusive. Based on claims data of 3.7 million statutory insurance members in Germany in 2015 the prevalence and incidence of PD was determined. PD cases...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinzel, Sebastian, Berg, Daniela, Binder, Sebastian, Ebersbach, Georg, Hickstein, Lennart, Herbst, Heinz, Lorrain, Michael, Wellach, Ingmar, Maetzler, Walter, Petersen, Gudula, Schmedt, Niklas, Volkmann, Jens, Woitalla, Dirk, Amelung, Volker
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033992/
https://www.ncbi.nlm.nih.gov/pubmed/30008693
http://dx.doi.org/10.3389/fneur.2018.00500
_version_ 1783337786939539456
author Heinzel, Sebastian
Berg, Daniela
Binder, Sebastian
Ebersbach, Georg
Hickstein, Lennart
Herbst, Heinz
Lorrain, Michael
Wellach, Ingmar
Maetzler, Walter
Petersen, Gudula
Schmedt, Niklas
Volkmann, Jens
Woitalla, Dirk
Amelung, Volker
author_facet Heinzel, Sebastian
Berg, Daniela
Binder, Sebastian
Ebersbach, Georg
Hickstein, Lennart
Herbst, Heinz
Lorrain, Michael
Wellach, Ingmar
Maetzler, Walter
Petersen, Gudula
Schmedt, Niklas
Volkmann, Jens
Woitalla, Dirk
Amelung, Volker
author_sort Heinzel, Sebastian
collection PubMed
description Epidemiological aspects of Parkinson's disease (PD), co-occurring diseases and medical healthcare utilization of PD patients are still largely elusive. Based on claims data of 3.7 million statutory insurance members in Germany in 2015 the prevalence and incidence of PD was determined. PD cases had at least one main hospital discharge diagnosis of PD, or one physician diagnosis confirmed by a subsequent or independent diagnosis or by PD medication in 2015. Prevalence of (co-)occurring diseases, mortality, and healthcare measures in PD cases and matched controls were compared. In 2015, 21,714 prevalent PD cases (standardized prevalence: 511.4/100,000 persons) and 3,541 incident PD cases (standardized incidence: 84.1/100,000 persons) were identified. Prevalence of several (co-)occurring diseases/complications, e.g., dementia (PD/controls: 39/13%), depression (45/22%), bladder dysfunction (46/22%), and diabetes (35/31%), as well as mortality (10.7/5.8%) differed between PD cases and controls. The annual healthcare utilization was increased in PD cases compared to controls, e.g., regarding mean ± SD physician contacts (15.2 ± 7.6/12.2 ± 7.3), hospitalizations (1.3 ± 1.8/0.7 ± 1.4), drug prescriptions (overall: 37.7 ± 24.2/21.7 ± 19.6; anti-PD medication: 7.4 ± 7.4/0.1 ± 0.7), assistive/therapeutic devices (47/30%), and therapeutic remedies (57/16%). The standardized prevalence and incidence of PD in Germany as well as mortality in PD may be substantially higher than reported previously. While frequently diagnosed with co-occurring diseases/complications, such as dementia, depression, bladder dysfunction and diabetes, the degree of healthcare utilization shows large variability between PD patients. These findings encourage a rethinking of the epidemiology and healthcare utilization in PD, at least in Germany. Longitudinal studies of insurance claims data should further investigate the individual and epidemiological progression and healthcare demands in PD.
format Online
Article
Text
id pubmed-6033992
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60339922018-07-13 Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? Heinzel, Sebastian Berg, Daniela Binder, Sebastian Ebersbach, Georg Hickstein, Lennart Herbst, Heinz Lorrain, Michael Wellach, Ingmar Maetzler, Walter Petersen, Gudula Schmedt, Niklas Volkmann, Jens Woitalla, Dirk Amelung, Volker Front Neurol Neurology Epidemiological aspects of Parkinson's disease (PD), co-occurring diseases and medical healthcare utilization of PD patients are still largely elusive. Based on claims data of 3.7 million statutory insurance members in Germany in 2015 the prevalence and incidence of PD was determined. PD cases had at least one main hospital discharge diagnosis of PD, or one physician diagnosis confirmed by a subsequent or independent diagnosis or by PD medication in 2015. Prevalence of (co-)occurring diseases, mortality, and healthcare measures in PD cases and matched controls were compared. In 2015, 21,714 prevalent PD cases (standardized prevalence: 511.4/100,000 persons) and 3,541 incident PD cases (standardized incidence: 84.1/100,000 persons) were identified. Prevalence of several (co-)occurring diseases/complications, e.g., dementia (PD/controls: 39/13%), depression (45/22%), bladder dysfunction (46/22%), and diabetes (35/31%), as well as mortality (10.7/5.8%) differed between PD cases and controls. The annual healthcare utilization was increased in PD cases compared to controls, e.g., regarding mean ± SD physician contacts (15.2 ± 7.6/12.2 ± 7.3), hospitalizations (1.3 ± 1.8/0.7 ± 1.4), drug prescriptions (overall: 37.7 ± 24.2/21.7 ± 19.6; anti-PD medication: 7.4 ± 7.4/0.1 ± 0.7), assistive/therapeutic devices (47/30%), and therapeutic remedies (57/16%). The standardized prevalence and incidence of PD in Germany as well as mortality in PD may be substantially higher than reported previously. While frequently diagnosed with co-occurring diseases/complications, such as dementia, depression, bladder dysfunction and diabetes, the degree of healthcare utilization shows large variability between PD patients. These findings encourage a rethinking of the epidemiology and healthcare utilization in PD, at least in Germany. Longitudinal studies of insurance claims data should further investigate the individual and epidemiological progression and healthcare demands in PD. Frontiers Media S.A. 2018-06-29 /pmc/articles/PMC6033992/ /pubmed/30008693 http://dx.doi.org/10.3389/fneur.2018.00500 Text en Copyright © 2018 Heinzel, Berg, Binder, Ebersbach, Hickstein, Herbst, Lorrain, Wellach, Maetzler, Petersen, Schmedt, Volkmann, Woitalla and Amelung. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Heinzel, Sebastian
Berg, Daniela
Binder, Sebastian
Ebersbach, Georg
Hickstein, Lennart
Herbst, Heinz
Lorrain, Michael
Wellach, Ingmar
Maetzler, Walter
Petersen, Gudula
Schmedt, Niklas
Volkmann, Jens
Woitalla, Dirk
Amelung, Volker
Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
title Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
title_full Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
title_fullStr Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
title_full_unstemmed Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
title_short Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
title_sort do we need to rethink the epidemiology and healthcare utilization of parkinson's disease in germany?
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033992/
https://www.ncbi.nlm.nih.gov/pubmed/30008693
http://dx.doi.org/10.3389/fneur.2018.00500
work_keys_str_mv AT heinzelsebastian doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT bergdaniela doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT bindersebastian doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT ebersbachgeorg doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT hicksteinlennart doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT herbstheinz doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT lorrainmichael doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT wellachingmar doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT maetzlerwalter doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT petersengudula doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT schmedtniklas doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT volkmannjens doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT woitalladirk doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany
AT amelungvolker doweneedtorethinktheepidemiologyandhealthcareutilizationofparkinsonsdiseaseingermany